source
- AstraZeneca reports Phase 3 trial shows Imfinzi-Padcev combo improves survival in bladder cancerAstraZeneca announced that its Phase 3 study of the immunotherapy Imfinzi combined with the antibody‑drug conjugate Padcev, developed with Pfizer and Astellas, extended overall survival for patient…
- Regenxbio reports key gene therapy results, moves toward FDA accelerated clearance for DuchenneRegenxbio said its experimental gene therapy RGX-202 met the primary endpoint in a pivotal Duchenne muscular dystrophy trial, positioning the company to file for accelerated FDA clearance. In the…